Cargando…

Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have demonstrated significant benefits to patients with non-small cell lung cancer (NSCLC) harboring EGFR-activating mutations; however, acquired resistance limits their long-term efficacy. Therefore, it remains an urgent requ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Yingjie, Bian, Dongliang, Zhang, Xuelin, Zhang, Huibiao, Zhu, Zhenghong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705995/ https://www.ncbi.nlm.nih.gov/pubmed/33200796 http://dx.doi.org/10.3892/mmr.2020.11686

Ejemplares similares

Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
por: Ritter, Violetta, et al.
Publicado: (2021)

Bcl-xL in neuroprotection and plasticity
por: Jonas, Elizabeth A., et al.
Publicado: (2014)

Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma
por: Yoshimine, S, et al.
Publicado: (2013)

Correction to: Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
por: Ritter, Violetta, et al.
Publicado: (2022)

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
por: He, Yonghan, et al.
Publicado: (2020)

Nutritional Regulators of Bcl-xL in the Brain
por: Park, Han-A, et al.
Publicado: (2018)

Mimicking Cdk2 phosphorylation of Bcl-xL at Ser73 results in caspase activation and Bcl-xL cleavage
por: Seng, NS, et al.
Publicado: (2016)

Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo
por: Karpel-Massler, Georg, et al.
Publicado: (2015)

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
por: Rooswinkel, R W, et al.
Publicado: (2012)

Molecular interactions of Bcl-2 and Bcl-xL with mortalin: identification and functional characterization
por: Saxena, Nishant, et al.
Publicado: (2013)

Bcl-xL as a Modulator of Senescence and Aging
por: Mas-Bargues, Cristina, et al.
Publicado: (2021)

Bcl-xL: A Focus on Melanoma Pathobiology
por: Lucianò, Anna Maria, et al.
Publicado: (2021)

Involvement of Bcl-xL in Neuronal Function and Development
por: Bas, Julie, et al.
Publicado: (2021)

The Role of Bcl-xL Protein in Viral Infections
por: Wyżewski, Zbigniew, et al.
Publicado: (2021)

Roles and Regulation of BCL-xL in Hematological Malignancies
por: Morales-Martínez, Mario, et al.
Publicado: (2022)

Advances in Bcl-xL Research 2.0
por: Kervadec, Joann, et al.
Publicado: (2023)

Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,
por: Lv, Dongwen, et al.
Publicado: (2021)

Nrz but not zBcl-xL antagonizes Bcl-wav pro-apoptotic activity in zebrafish
por: Prudent, Julien, et al.
Publicado: (2014)

Disruption of Bcl-2 and Bcl-xL by viral proteins as a possible cause of cancer
por: Alibek, Kenneth, et al.
Publicado: (2014)

Inhibition of Bcl-xL prevents pro-death actions of ΔN-Bcl-xL at the mitochondrial inner membrane during glutamate excitotoxicity
por: Park, Han-A, et al.
Publicado: (2017)

Dynamics of Bcl-xL in Water and Membrane: Molecular Simulations
por: Maity, Atanu, et al.
Publicado: (2013)

Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin
por: Baranski, Zuzanna, et al.
Publicado: (2015)

Regulation of apoptosis by an intrinsically disordered region of Bcl-xL
por: Follis, Ariele Viacava, et al.
Publicado: (2018)

The Role of Bcl-xL Protein Research in Veterinary Oncology
por: Pawlak, Aleksandra, et al.
Publicado: (2020)

Bcl-xL activity influences outcome of the mitotic arrest
por: Suleimenov, M., et al.
Publicado: (2022)

Functional impact of cancer patient‐associated Bcl‐xL mutations
por: Zhang, Tiantian, et al.
Publicado: (2020)

Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems
por: Shang, Enyuan, et al.
Publicado: (2018)

Bioinformatic Analysis of the BCL-xL/BCL2L1 Interactome in Patients with Pancreatic Cancer
por: Magouliotis, Dimitrios E., et al.
Publicado: (2022)

Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL
por: Yosef, Reut, et al.
Publicado: (2016)

Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy
por: Westhoff, Mike-Andrew, et al.
Publicado: (2022)

Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma
por: Zhang, Yiru, et al.
Publicado: (2018)

Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer
por: Lopez, Andrea, et al.
Publicado: (2022)

ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL
por: Li, Ji-Yu, et al.
Publicado: (2012)

Targeting BCL-XL in fibrolamellar hepatocellular carcinoma
por: Shebl, Bassem, et al.
Publicado: (2022)

Bcl-xL affects the development of functional CD4 Tregs
por: Sharabi, Amir, et al.
Publicado: (2010)

Bcl-xL inhibition - a novel strategy for glioma therapy
por: Karpel-Massler, Georg, et al.
Publicado: (2016)

ΔN-Bcl-xL, a therapeutic target for neuroprotection
por: Park, Han-A, et al.
Publicado: (2017)

Retromer facilitates the localization of Bcl-xL to the mitochondrial outer membrane
por: Farmer, Trey, et al.
Publicado: (2019)

Effects of Cardiolipin on the Conformational Dynamics of Membrane-Anchored Bcl-xL
por: Tyagi, Vivek, et al.
Publicado: (2021)

Bcl-XL and Bcl-2 repress a common pathway of cell death
Publicado: (1995)

Cannot write session to /tmp/vufind_sessions/sess_5jpk8qbpeb7n6otub1fr97s8qf